WHO Register of non-State actors

Disclaimer:

Information regarding a non-State actor, contained in the section “Non-State Actors Profiles” in the Register, has been provided by that non-State actor itself, and the accuracy and completeness of such information is the sole responsibility of that non-State actor, not WHO. In turn, information in the sections “WHO’s Engagement” and “Non-State Actors in Official Relations” has been provided by WHO, subject to certain conditions. All access and use of any section of the Register is governed by the Terms and Conditions of Use.

Overview

Official name

World Federation of Nuclear Medicine and Biology

Acronym (if applicable)

WFNMB

Short self description

The World Federation of Nuclear Medicine and Biology (WFNMB) is a global umbrella organisation for Nuclear Medicine, Hybrid Imaging and Biology. One of WFNMB’s principal activities is, to support education efforts for nuclear physicians, physicists, radio-pharmacists, radiochemists, technologists and other nuclear medicine scientists, especially from the developing world.

Website

www.wfnmb.org

Web link to health relevant activities

Parent entity (if applicable)

The entity you represent is indicated as a parent of the following entities in the Register:

N / A

Date submitted

07 Oct 2024 01:51:31 PM

General information

Name

Official name

World Federation of Nuclear Medicine and Biology

Acronym (if applicable)

WFNMB

Commonly used name (if applicable)

World Federation of Nuclear Medicine and Biology

Names in other official languages (if applicable) Name Abbreviation

Former name

Short self description

Address Contact

Address 1

Schmalzhofgasse 26, 5.OG

Address 2

c/o EANM Office

Address 3

Town/City

Vienna

State/Region

Postal code

1060

Country

Austria

Email (generic)

office@wfnmb.org

Related links

Website

www.wfnmb.org

Governance

Legal status

In Austria registered non-profit Association (since 2011)

Year established

1970

Governance structure

Description of main decision making bodies (e.g. board, board of directors, executive board, executive committee, etc).

Name of body

Executive Board

Composition and current list of members Name Function Affiliation

Lizette Louw

President

CH Baragwanath Academic Hospital, Johannesburg, South Africa

Gopinath Gnanasegaran

Secretary

Royal Free London NHS Foundation Trust, UK

Francois Lamoureux

Treasurer

Department of Nuclear Medicine, Radiology and Radiotherapy at the Faculty of Medicine of the University of Montréal, Canada

Savvas Frangos

President Elect

Bank of Cyprus Oncology Centre, Cyprus

Helen R. Nadel

Representative Society of Nuclear Medicine and Molecular Imaging

Stanford Hospital Stanford, CA

Rudi Dierckx

Representative European Association of Nuclear Medicine

University of Groningen, Netherlands

Keon Wook Kang

Representative Asian Regional Cooperative Council for Nuclear Medicine

Seoul National University

Gang Huang

Representative Asia Oceania Federation of Nuclear Medicine and Biology

Shanghai University of Medicine & Health Sciences(SUMHS), China

Gisela Estrada

Representative Asociación Latinoamericana de Sociedades de Biología y Medicina Nuclear

Sanatorio San Gerónimo, Santa Fe, Argentinia

Salah Eddine Bouyoucef

Representative Africa Association of Nuclear Medicine

CHU Babel Oued, Algiers, Algeria

Roslyn Francis

Representative Australian And New Zealand Society Of Nuclear Medicine

Sir Charles Gairdner Hospital, Nedlands WA,Australia

Diana Paez

Representative International Atomic Energy Agency

IAEA, Vienna, Austria

John Prior

WFNMB focal point for technical collaboration with WHO

Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Akram Al-Ibrahim

Representative Arabic Society of Nuclear Medicine

King Hussein Cancer Center, Amman, Jordan

Jean-Luc Urbain

Past-President

Wake Forest University, Nuclear Medicine, North Carolina, USA

Functions

Governance and representation of the Federation

Name of body

Composition and current list of members Name Function Affiliation

Functions

General Assembly

Does the entity have a General Assembly of members or a similar body?

Yes

Name

Delegate's Assembly

Composition

One delegate per member country in good standing, is allowed to attend the annual assembly, including the right to vote in the event of elections

Functions

(see also the official statues at http://www.wfnmb.org/?page_id=19)
• Receive the Annual Report of the President, Secretary General and Treasurer.
• Approve the nomination or deposition of members of the Executive Board and
auditors.
• Resolution on amendments of the Statutes.
• Fix the index for dues to be paid by member societies or groups.
• Grant exemption to the obligation to pay dues to any society or group which it
deems has shown due cause why such exemption should be granted.
• Approve the site for the Federation Executive Office.
• Approve and define subsidiary bodies. Subsidiary bodies shall be operational
bodies functioning under the Federation. The roles and administration of these
organs shall be specified in their rules and regulations.
• Resolution on the dissolution of the Federation.
• Voting for the site for the Federation Congress to be held six (6) years
subsequently. In the course of this election, the positions of the next Congress Chair, the Scientific Program Committee Chair as well as the Budget Committee Chair will be announced. Their office starts with January 1, two (2) years after the respective Assembly and lasts for four (4) years. The filling of the offices is part of the candidacies for the congress site of the Federation. The selection of the persons is not subject to of the vote of the General Assembly.

Financial information

Latest available annual income (month/year)

From

January

2023

December

2023

Annual income (USD)

110,912

Latest available assets (month/year)

As of

December

2023

Total assets (USD)

321,906

Income sources (in USD)

Income source Income type

Private sector entities (including business associations)

Philanthropic foundations

NGOs, academic institutions

Government entities, intergovernmental organizations, including UN

General public, individuals

Total

Sales of goods and services *

Grants / Donations

11,871

In-kind donations

Membership fees

20,400

Investment income

Others

89,756

Total

122,027

* income from congresses / conferences should be listed under Sales of goods and services

Additional information

Grant belongs to LOC (Lancet Oncology Commission) - WFNMB has supported Andrew Scott in collecting the money for the Lancet Oncology Commission

Membership

Entity's members

Is the entity you represent membership based?

Yes

Overview of categories and their voting rights in the main governing body:

Total number Voting

Individuals

NGOs

Private sector entities

Philanthropic foundations

Academic institutions

Government entities

Intergovernmental organizations

Organizational Structure

Parent entity

In the register Registered Entity Entity Name

No data available

Yes

Legal status

Affiliated entities (or subsidiaries)

In the register Registered Entity Entity Name

No data available

Relations

Entity's membership in other entities

In the register Registered Entity Entity Name Type of membership

No data available

Members of the entity

In the register Registered Entity Member Name

No data available

Activities

Aims (or purposes, objectives) of the entity as they appear in its constitution or by-laws or equivalent document.

The Federation is a voluntary non-profit making organisation of societies/associations or groups associated for the following purposes
• To organise congresses, workshops and other educational activities covering all aspects of Nuclear Medicine and Biology
• To develop co-operation between societies/associations or groups active in Nuclear Medicine and Biology
• To promote the development of Nuclear Medicine and Biology
• To facilitate the exchange of scientists between the member societies/associations or
groups and to set up a body which will centralize and help such exchange
• To prepare and recommend the organization of a unified programme of teaching and
training in the field of Nuclear Medicine and Biology
• To establish technical standards, to aid in the diffusion of knowledge and exchange of
scientific and technical information by means of conferences, colloquia, symposia and
courses on regional, national and international levels
• To publish, alone or in collaboration, monographs, studies, teaching, courses, reports
from conferences, colloquia, symposia and congresses concerning Nuclear Medicine
and Biology
• To represent with one voice all Nuclear Medicine activities to the World Health
Organization, the International Atomic Energy Agency and other appropriate
organizations
• To organize whatever commissions and meetings are necessary to attain such
objectives
• To work with and support WFNMB subsidiary organizations and related organisations
to promote worldwide expansion of Nuclear Medicine and Biology

The activities of the entity are related to the following strategic priorities and outcomes of the current WHO's General Programme of Work:

Strategic objective 1: Respond to climate change, an escalating health threat in the 21st century

Joint outcome 1.1. More climate-resilient health systems are addressing health risks and impacts

Joint outcome 1.2. Lower-carbon health systems and societies are contributing to health and well-being

Strategic objective 2: Address health determinants and the root causes of ill health in key policies across sectors

Joint outcome 2.1. Health inequities reduced by acting on social, economic, environmental and other determinants of health

Joint outcome 2.2. Priority risk factors for noncommunicable and communicable diseases, violence and injury, and poor nutrition, reduced through multisectoral approaches

Joint outcome 2.3. Populations empowered to control their health through health promotion programmes and community involvement in decision-making

Strategic objective 3: Advance the primary health care approach and essential health system capacities for universal health coverage

Joint outcome 3.1. The primary health care approach renewed and strengthened to accelerate universal health coverage

Joint outcome 3.2. Health and care workforce, health financing and access to quality-assured health products substantially improved

Joint outcome 3.3. Health information systems strengthened and digital transformation implemented.

Strategic objective 4: Improve health service coverage and financial protection to address inequity and gender inequalities

Joint outcome 4.1. Equity in access to quality services improved for noncommunicable diseases, mental health conditions and communicable diseases, while addressing antimicrobial resistance

Joint outcome 4.2. Equity in access to sexual, reproductive, maternal, newborn, child, adolescent and older person health and nutrition services and immunization coverage improved

Joint outcome 4.3. Financial protection improved by reducing financial barriers and out-of-pocket health expenditures, especially for the most vulnerable

Strategic objective 5: Prevent, mitigate and prepare for risks to health from all hazards

Joint outcome 5.1. Risks of health emergencies from all hazards reduced and impact mitigated

Joint outcome 5.2. Preparedness, readiness and resilience for health emergencies enhanced

Strategic objective 6: Rapidly detect and sustain an effective response to all health emergencies

Joint outcome 6.1. Detection of and response to acute public health threats is rapid and effective

Joint outcome 6.2. Access to essential health services during emergencies is sustained and equitable

Additional information on the entity's activities

WFNMB organises every 4 years a world congress for Nuclear Medicine, Biology and related disciplines. The congress organisation as well as the finances involved, are handled by the Local Organising Bodies. WFNMB receives a minimum revenue of USD 50,000.- from the congress.

Country presence

Countries where the entity has activities, members and regional offices / representatives:

Regions

Countries

Activities

Members

Offices / representatives

African Region

Region of the Americas

Eastern Mediterranean Region

European Region

South-East Asia Region

Western Pacific Region

Global

Disclosure & declaration

Tobacco/Arms related disclosure statement for non-State actors

Pursuant the WHO Framework of Engagement with Non-State Actors, WHO does not engage with the tobacco industry or non-State actors that work to further the interests of the tobacco industry. WHO also does not engage with the arms industry.

For the purposes of this statement:

tobacco industry means any entity involved in the manufacture, sale or distribution of tobacco and related products, and any affiliate of such entity; and
arms industry means any entity involved in the manufacture, sale or distribution of arms, and any affiliate of such entity.

This disclosure statement needs to be provided by any nongovernmental organization, private sector entity, philanthropic foundation and academic institution prior to engaging with WHO.

In view of the foregoing, please answer the following questions:

Is your entity, or was your entity over the last four years, part of the tobacco or arms industries (as defined above)?

Yes

No

Unable to answer

To the best of your entity’s knowledge, is your entity, or has your entity over the last four years, engaged in activities that are aimed at furthering or supporting the interests of the tobacco industry? This includes, but is not limited to, supply contracts, contract work, services and lobbying.

Yes

No

Unable to answer

To the best of your entity’s knowledge, does your entity currently, or did your entity over the last four years, have any other association or relationship with the tobacco industry (as defined above). This includes in particular investment interests (other than general mutual funds or similar arrangements whereby your entity has no control over the selection of the investments), commercial business interests, the provision or receipt of financial and/or other support.

Yes

No

Unable to answer

If you have answered yes to any of the above or are unable to answer one or more questions, please provide a general statement of explanation.

Please note that the WHO Secretariat reserves the right to request additional information from your entity in this regard.

By providing this statement, your entity commits to promptly inform WHO of any change to the above information and to complete a new statement that describes the changes.

Engagement with other industries affecting human health or affected by WHO norm and standards

Does the entity you represent have any formal association, affiliation or links with the following industry sectors?

If yes, please tick the box of the industry concerned and provide details in the space provided:

Alcohol

Chemical

Food and beverages

Health care

Pharmaceutical

Others

Please specify industry

WHO Secretariat reserves the right to request additional information from the entity you represent relevant to its engagement with WHO.

*Sexual Exploitation, Abuse and Harassment (SEAH) and Misconduct (abusive or fraudulent)

Entities engaging with WHO are expected to ensure that the conduct of their employees and any other persons engaged by them to perform any activities or to provide any services for WHO on behalf of the entities is consistent with the WHO standards of conduct. In particular, WHO has zero tolerance towards any form of sexual misconduct, which includes sexual exploitation, sexual abuse, sexual violence, and sexual harassment, and other types of abusive or fraudulent conduct. In the view of the forgoing, please confirm that your entity shall:

Take all reasonable and appropriate measures to prevent sexual misconduct as defined in WHO’s Policy on Preventing and Addressing Sexual Misconduct, and other types of abusive or fraudulent conduct as defined, respectively, in WHO’s Policy on Preventing and Addressing Abusive Conduct and in WHO’s Policy on Prevention, Detection and Response to Fraud and Corruption by any of its employees and by any other persons engaged by it to perform any activities or to provide any services for WHO on the entity’s behalf;

Promptly report to WHO’s Office of Internal Oversight Services (IOS) at investigation@who.int any actual or suspected misconduct, as defined by WHO in these Policies and of which the entity becomes aware;

Promptly communicate to IOS any measures that may be necessary or appropriate to protect the confidentiality and wellbeing of the alleged victim;

Promptly respond to any actual or suspected misconduct as defined by WHO in these Policies of which the entity becomes aware; and

To cooperate with IOS and keep IOS informed of the status and outcome of any measures of protection, corrections to operations, investigation, and disciplinary action taken against any perpetrator by the entity.

Date submitted